Island Pharmaceuticals Ltd has released a press release.
Island receives FDA feedback on Phase 2a clinical study
Filed with ASX ·
6ix hasn’t read this filing yet.
Island Pharmaceuticals Ltd on 6ix
Story so far
Earlier from Island Pharmaceuticals
- ILA submits IND to US FDA for Phase 2a PEACH clinical trial
- IRB approval received for ISLA101 Phase 2a clinical trial
- ISLA101 drug product achieves stability milestone
- ILA granted key Canadian patent for ISLA-101
- Positive analytical results for ISLA-101 capsules
Later from Island Pharmaceuticals
- ILA receives additional FDA feedback on IND for ISLA 101
- Island submits responses to FDA questions for ISLA-101
- Island receives FDA go-ahead for ISLA-101 program
- US grant funding to support ISLA-101 clinical development
- Appendix 4E & Annual Report
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals